[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569187":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":63,"collaborators":65,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 18F-S16\u002FT807, and undergo PET\u002FCT or MRI imaging within the specificed time.",[13],"Diagnostic Test: 18F-S16\u002FT807",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","18F-S16\u002FT807",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ying Wang, MD","CONTACT","+8618702292537","macrossplusvoices@163.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Shaobo Yao, PhD","+862260362190","yaoshaobo008@163.com",[30,51],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230000","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.28083,31.86389,{"lat":42,"lon":41},[45,49],{"name":46,"role":22,"phone":47,"phoneExt":10,"email":48},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"name":46,"role":50,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":52,"status":32,"city":53,"state":54,"zip":55,"country":36,"countryCode":37,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052",{"type":39,"coordinates":57},[58,59],117.17667,39.14222,{"lat":59,"lon":58},[62],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":50,"investigatorFullName":26,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof.",[66],{"name":52,"class":6},"100569187","tau-petct-in-various-tau-related-disease-patients-100569187",false,"NCT06690983","Tau PET\u002FCT in Various Tau-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":78,"type":79},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 18F-S16\u002FT807 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[84,85,86],"Tauopathies","Neurodegenerative Diseases","Neurodegeneration",[88,89,90],"PET\u002FCT","MRI","Tau","2025-02-07",{"date":93,"type":94},"2025-02-11","ACTUAL",{"date":96,"type":94},"2018-08-01",{"date":98,"type":79},"2027-12-01",{"name":5,"class":6},2]